Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

18 Jul 2023
Bezlotoxumab prevents CDI recurrence in immunocompromised patients

Bezlotoxumab prevents CDI recurrence in immunocompromised patients

16 Jul 2023
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab

Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab

15 Jul 2023

Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.

Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab

15 Jul 2023
Long-acting ART induces viral suppression in people with HIV

Long-acting ART induces viral suppression in people with HIV

15 Jul 2023

People with HIV (PWH) who are treated with long-acting (LA) antiretroviral therapy (ART) achieve virologic suppression, as do those with viraemia and challenges to adherence, reports a study.

Long-acting ART induces viral suppression in people with HIV

15 Jul 2023
Ustekinumab shows efficacy in Asians with plaque psoriasis

Ustekinumab shows efficacy in Asians with plaque psoriasis

14 Jul 2023 bởiStephen Padilla

Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.

Ustekinumab shows efficacy in Asians with plaque psoriasis

14 Jul 2023
Virtual ward feasible home-based care strategy for high-risk COVID-19 patients

Virtual ward feasible home-based care strategy for high-risk COVID-19 patients

07 Jul 2023
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023